Gastric cancer patient-derived organoids model for the therapeutic drug screening
Gastric cancer (GC) is a highly heterogeneous disease featuring many various histological and molecular subtypes. Therefore, it is imperative to have well-characterized in vitro models for personalized treatment development. Gastric cancer patient-derived organoids (PDOs), re-capitulating in vivo co...
Saved in:
| Published in | Biochimica et biophysica acta. General subjects Vol. 1868; no. 4; p. 130566 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier B.V
01.04.2024
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Gastric cancer (GC) is a highly heterogeneous disease featuring many various histological and molecular subtypes. Therefore, it is imperative to have well-characterized in vitro models for personalized treatment development. Gastric cancer patient-derived organoids (PDOs), re-capitulating in vivo conditions, exhibit high clinical efficacy in predicting drug sensitivity to facilitate the development of cancer precision medicine.
PDOs were established from surgically resected GC tumor tissues. Histological and molecular characterization of PDOs and primary tissues were performed via IHC and sequencing analysis. We also conducted drug sensitivity tests using PDO cultures with five chemotherapeutic drugs and twenty-two targeted drugs.
We have successfully constructed a PDOs biobank that included EBV+, intestinal/CIN, diffuse/GS, mixed and Her2+ GC subtypes, and these PDOs captured the pathological and genetic characteristics of corresponding tumors and exhibited different sensitivities to the tested agents. In a clinical case study, we performed an additional drug sensitivity test for a patient who reached an advanced progressive stage after surgery. We discovered that the combination of napabucasin and COTI-2 exhibited a stronger synergistic effect than either drug alone.
PDOs maintained the histological and genetic characteristics of original cancer tissues. PDOs biobank opens up new perspectives for studying cancer cell biology and personalized medicine as a preclinical study platform.
•Living biobank encompassed 18 normal and 21 gastric cancer organoids.•Established organoids biobank included most of the known subtypes of gastric cancer.•High-throughput screening revealed potential targeted drugs for personalized medicine.•Napabucasin combined with COTI-2 indicated a potential therapy strategy for advanced progressive patients of gastric cancer. |
|---|---|
| AbstractList | Gastric cancer (GC) is a highly heterogeneous disease featuring many various histological and molecular subtypes. Therefore, it is imperative to have well-characterized in vitro models for personalized treatment development. Gastric cancer patient-derived organoids (PDOs), re-capitulating in vivo conditions, exhibit high clinical efficacy in predicting drug sensitivity to facilitate the development of cancer precision medicine.
PDOs were established from surgically resected GC tumor tissues. Histological and molecular characterization of PDOs and primary tissues were performed via IHC and sequencing analysis. We also conducted drug sensitivity tests using PDO cultures with five chemotherapeutic drugs and twenty-two targeted drugs.
We have successfully constructed a PDOs biobank that included EBV+, intestinal/CIN, diffuse/GS, mixed and Her2+ GC subtypes, and these PDOs captured the pathological and genetic characteristics of corresponding tumors and exhibited different sensitivities to the tested agents. In a clinical case study, we performed an additional drug sensitivity test for a patient who reached an advanced progressive stage after surgery. We discovered that the combination of napabucasin and COTI-2 exhibited a stronger synergistic effect than either drug alone.
PDOs maintained the histological and genetic characteristics of original cancer tissues. PDOs biobank opens up new perspectives for studying cancer cell biology and personalized medicine as a preclinical study platform.
•Living biobank encompassed 18 normal and 21 gastric cancer organoids.•Established organoids biobank included most of the known subtypes of gastric cancer.•High-throughput screening revealed potential targeted drugs for personalized medicine.•Napabucasin combined with COTI-2 indicated a potential therapy strategy for advanced progressive patients of gastric cancer. Gastric cancer (GC) is a highly heterogeneous disease featuring many various histological and molecular subtypes. Therefore, it is imperative to have well-characterized in vitro models for personalized treatment development. Gastric cancer patient-derived organoids (PDOs), re-capitulating in vivo conditions, exhibit high clinical efficacy in predicting drug sensitivity to facilitate the development of cancer precision medicine.BACKGROUNDGastric cancer (GC) is a highly heterogeneous disease featuring many various histological and molecular subtypes. Therefore, it is imperative to have well-characterized in vitro models for personalized treatment development. Gastric cancer patient-derived organoids (PDOs), re-capitulating in vivo conditions, exhibit high clinical efficacy in predicting drug sensitivity to facilitate the development of cancer precision medicine.PDOs were established from surgically resected GC tumor tissues. Histological and molecular characterization of PDOs and primary tissues were performed via IHC and sequencing analysis. We also conducted drug sensitivity tests using PDO cultures with five chemotherapeutic drugs and twenty-two targeted drugs.METHODSPDOs were established from surgically resected GC tumor tissues. Histological and molecular characterization of PDOs and primary tissues were performed via IHC and sequencing analysis. We also conducted drug sensitivity tests using PDO cultures with five chemotherapeutic drugs and twenty-two targeted drugs.We have successfully constructed a PDOs biobank that included EBV+, intestinal/CIN, diffuse/GS, mixed and Her2+ GC subtypes, and these PDOs captured the pathological and genetic characteristics of corresponding tumors and exhibited different sensitivities to the tested agents. In a clinical case study, we performed an additional drug sensitivity test for a patient who reached an advanced progressive stage after surgery. We discovered that the combination of napabucasin and COTI-2 exhibited a stronger synergistic effect than either drug alone.RESULTSWe have successfully constructed a PDOs biobank that included EBV+, intestinal/CIN, diffuse/GS, mixed and Her2+ GC subtypes, and these PDOs captured the pathological and genetic characteristics of corresponding tumors and exhibited different sensitivities to the tested agents. In a clinical case study, we performed an additional drug sensitivity test for a patient who reached an advanced progressive stage after surgery. We discovered that the combination of napabucasin and COTI-2 exhibited a stronger synergistic effect than either drug alone.PDOs maintained the histological and genetic characteristics of original cancer tissues. PDOs biobank opens up new perspectives for studying cancer cell biology and personalized medicine as a preclinical study platform.CONCLUSIONPDOs maintained the histological and genetic characteristics of original cancer tissues. PDOs biobank opens up new perspectives for studying cancer cell biology and personalized medicine as a preclinical study platform. Gastric cancer (GC) is a highly heterogeneous disease featuring many various histological and molecular subtypes. Therefore, it is imperative to have well-characterized in vitro models for personalized treatment development. Gastric cancer patient-derived organoids (PDOs), re-capitulating in vivo conditions, exhibit high clinical efficacy in predicting drug sensitivity to facilitate the development of cancer precision medicine. PDOs were established from surgically resected GC tumor tissues. Histological and molecular characterization of PDOs and primary tissues were performed via IHC and sequencing analysis. We also conducted drug sensitivity tests using PDO cultures with five chemotherapeutic drugs and twenty-two targeted drugs. We have successfully constructed a PDOs biobank that included EBV+, intestinal/CIN, diffuse/GS, mixed and Her2+ GC subtypes, and these PDOs captured the pathological and genetic characteristics of corresponding tumors and exhibited different sensitivities to the tested agents. In a clinical case study, we performed an additional drug sensitivity test for a patient who reached an advanced progressive stage after surgery. We discovered that the combination of napabucasin and COTI-2 exhibited a stronger synergistic effect than either drug alone. PDOs maintained the histological and genetic characteristics of original cancer tissues. PDOs biobank opens up new perspectives for studying cancer cell biology and personalized medicine as a preclinical study platform. |
| ArticleNumber | 130566 |
| Author | Qi, Xin Yu, Bixin Yang, Jin Gong, Jin Li, Mengyang Xu, Jiao Kang, Ye Liang, Xiao Ma, Jinrong Wang, Xi |
| Author_xml | – sequence: 1 givenname: Jiao surname: Xu fullname: Xu, Jiao organization: Precision Medicine Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China – sequence: 2 givenname: Jin surname: Gong fullname: Gong, Jin organization: Cancer Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China – sequence: 3 givenname: Mengyang surname: Li fullname: Li, Mengyang organization: Precision Medicine Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China – sequence: 4 givenname: Ye surname: Kang fullname: Kang, Ye organization: MED-X Institute, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China – sequence: 5 givenname: Jinrong surname: Ma fullname: Ma, Jinrong organization: Precision Medicine Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China – sequence: 6 givenname: Xi surname: Wang fullname: Wang, Xi organization: Department of Medical Oncology, Shaanxi Provincial People's Hospital, Xi'an 710068, China – sequence: 7 givenname: Xiao surname: Liang fullname: Liang, Xiao organization: Cancer Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China – sequence: 8 givenname: Xin surname: Qi fullname: Qi, Xin organization: Precision Medicine Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China – sequence: 9 givenname: Bixin surname: Yu fullname: Yu, Bixin organization: Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China – sequence: 10 givenname: Jin surname: Yang fullname: Yang, Jin email: yangjin@xjtu.edu.cn organization: Precision Medicine Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38244703$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkEtr3DAURkVJSCZp_kEpXmbjydXDspxFoYTmAYFQaNdClq6nGjzSRJID-ff14GTTRSO4aHPOtzhn5CjEgIR8obCmQOXVdt33ZoNhzYCJNeXQSPmJrKhqWa0A5BFZAQdRCyqbU3KW8xbm13TNCTnlignRAl-Rn3cml-RtZU2wmKq9KR5DqR0m_4KuimljQvQuV7vocKyGmKryBw-XzB6nMqsuTZsq24QYfNh8JseDGTNevP3n5Pftj1839_Xj093DzffH2nLJSo1McuXM0FpOuXAUmqETygFVrh9s76RrnGFS9a5V0vCBGeg7C44JSxW2yM_J5bK7T_F5wlz0zmeL42gCxilr1lHVUAodzOjXN3Tqd-j0PvmdSa_6PcMMXC-ATTHnhIO2vswlYijJ-FFT0IfmequX5vrQXC_NZ1n8I7_vf6B9WzScI714TDrbOb1F5xPaol30_x_4CyRYnT4 |
| CitedBy_id | crossref_primary_10_3390_organoids3040016 |
| Cites_doi | 10.15252/embj.2019101654 10.1186/s13045-019-0829-z 10.1016/j.cell.2018.07.027 10.3322/caac.21660 10.1016/S0140-6736(10)61121-X 10.1159/000512833 10.1016/j.biopha.2023.114751 10.1158/1078-0432.CCR-19-0096 10.3791/61443 10.1136/gutjnl-2014-307595 10.1016/j.tibtech.2017.12.005 10.3390/biomedicines7010017 10.1136/gutjnl-2017-314549 10.1200/JCO.2010.33.0597 10.1016/j.stem.2018.09.016 10.1158/0008-5472.CAN-09-3788 10.1158/2159-8290.CD-21-0683 10.1007/s11864-020-00774-4 10.1016/j.devcel.2016.08.014 10.1126/science.aao2774 10.3390/cancers13246158 10.1038/ng.2983 10.1089/omi.2011.0118 10.1056/NEJMoa1112088 10.3390/cancers15010269 10.1038/s41392-022-01190-w 10.1155/2022/2353115 10.1186/s42826-020-00045-1 10.3322/caac.21657 10.1186/s12943-023-01796-w 10.1073/pnas.1424171112 10.1016/j.gde.2013.11.012 10.1158/2159-8290.CD-20-1109 10.3748/wjg.v22.i30.6776 10.1038/s41575-019-0255-2 10.1093/nar/gkw1092 10.1158/1078-0432.CCR-12-1318 10.1016/S0140-6736(20)31288-5 10.1038/nature13480 |
| ContentType | Journal Article |
| Copyright | 2024 The Authors Copyright © 2024. Published by Elsevier B.V. |
| Copyright_xml | – notice: 2024 The Authors – notice: Copyright © 2024. Published by Elsevier B.V. |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.bbagen.2024.130566 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Chemistry Biology |
| EISSN | 1872-8006 |
| ExternalDocumentID | 38244703 10_1016_j_bbagen_2024_130566 S0304416524000096 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- --K --M .~1 0R~ 1B1 1RT 1~. 1~5 23N 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 6I. 7-5 71M 8P~ 9JM AACTN AAEDT AAEDW AAFTH AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAXUO ABEFU ABFNM ABGSF ABMAC ABUDA ABXDB ABYKQ ACDAQ ACIUM ACRLP ADBBV ADEZE ADMUD ADUVX AEBSH AEHWI AEKER AFKWA AFTJW AFXIZ AGHFR AGRDE AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJBFU AJOXV ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC CS3 DOVZS EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HLW HVGLF HZ~ IHE J1W KOM LX3 M41 MO0 N9A O-L O9- OAUVE OHT OZT P-8 P-9 PC. Q38 R2- ROL RPZ SBG SCC SDF SDG SDP SES SEW SPCBC SSU SSZ T5K UQL WH7 WUQ XJT XPP ~G- AAHBH AATTM AAXKI AAYWO AAYXX ABWVN ACRPL ACVFH ADCNI ADNMO AEIPS AEUPX AFJKZ AFPUW AGCQF AGQPQ AGRNS AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP BNPGV CITATION SSH CGR CUY CVF ECM EFKBS EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c362t-e2638daf7c3134d105f948d018dbfcbd6d5da268bd786a3f2a0b9c0d24c18e7e3 |
| IEDL.DBID | .~1 |
| ISSN | 0304-4165 1872-8006 |
| IngestDate | Fri Jul 11 03:58:16 EDT 2025 Mon Jul 21 06:02:01 EDT 2025 Tue Jul 01 00:22:19 EDT 2025 Thu Apr 24 23:07:35 EDT 2025 Sat Mar 02 16:00:55 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Organoids biobank COTI-2 Napabucasin Personalized medicine Gastric cancer |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2024. Published by Elsevier B.V. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c362t-e2638daf7c3134d105f948d018dbfcbd6d5da268bd786a3f2a0b9c0d24c18e7e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0304416524000096 |
| PMID | 38244703 |
| PQID | 2918511090 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2918511090 pubmed_primary_38244703 crossref_citationtrail_10_1016_j_bbagen_2024_130566 crossref_primary_10_1016_j_bbagen_2024_130566 elsevier_sciencedirect_doi_10_1016_j_bbagen_2024_130566 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | April 2024 2024-04-00 20240401 |
| PublicationDateYYYYMMDD | 2024-04-01 |
| PublicationDate_xml | – month: 04 year: 2024 text: April 2024 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Biochimica et biophysica acta. General subjects |
| PublicationTitleAlternate | Biochim Biophys Acta Gen Subj |
| PublicationYear | 2024 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Greshock, Bachman, Degenhardt, Jing, Wen, Eastman, McNeil, Moy, Wegrzyn, Auger, Hardwicke, Wooster (bb0030) 2010; 70 Lindemann, Patel, Silver, Tang, Liu, Wang, Tanaka, Rao, Takahashi, Maduka, Zhao, Chen, Liu, Gao, Wang, Frank, Hittelman, Mills, Myers, Osman (bb0100) 2019; 25 Yin, Liu, Zhou, Xu, Wang, Chen, Deng, Wang, Yu, Gu, Huo, Li, Zeng, He, Zhang (bb0200) 2023; 10 Lau, Kranenburg, Xiao, Yu (bb0045) 2020; 17 Yan, Siu, Law, Ho, Yue, Tsui, Chan, Chan, Ma, Lam, Bartfeld, Man, Lee, Chan, Wong, Cheng, Chan, Zhang, Shi, Fan, Kwong, Mak, Yuen, Clevers, Leung (bb0075) 2018; 23 Jeong, Eun, Lee, Kang, Yim, Kim, Noh, Sohn, Woo, Kong, Nam, Jang, Lee, Song, Oh, Lee, Ajani, Lee (bb0025) 2023; 22 Vlachogiannis, Hedayat, Vatsiou, Jamin, Fernandez-Mateos, Khan, Lampis, Eason, Huntingford, Burke, Rata, Koh, Tunariu, Collins, Hulkki-Wilson, Ragulan, Spiteri, Moorcraft, Chau, Rao, Watkins, Fotiadis, Bali, Darvish-Damavandi, Lote, Eltahir, Smyth, Begum, Clarke, Hahne, Dowsett, de Bono, Workman, Sadanandam, Fassan, Sansom, Eccles, Starling, Braconi, Sottoriva, Robinson, Cunningham, Valeri (bb0070) 2018; 359 Zu, Hao, Ning, Zhou, Gong, Lang, Xu, Zhang, Ding (bb0170) 2023; 163 van Hagen, Hulshof, van Lanschot, Steyerberg, van Berge Henegouwen, Wijnhoven, Richel, Nieuwenhuijzen, Hospers, Bonenkamp, Cuesta, Blaisse, Busch, ten Kate, Creemers, Punt, Plukker, Verheul, Spillenaar Bilgen, van Dekken, van der Sangen, Rozema, Biermann, Beukema, Piet, van Rij, Reinders, Tilanus, van der Gaast, C. Group (bb0140) 2012; vol. 366 Bang, Van Cutsem, Feyereislova, Chung, Shen, Sawaki, Lordick, Ohtsu, Omuro, Satoh, Aprile, Kulikov, Hill, Lehle, Rüschoff, Kang (bb0180) 2010; 376 Chakrabarti, Koh, So, Yong, Zavros (bb0155) 2021 Shah, Shitara, Lordick, Bang, Tebbutt, Metges, Muro, Lee, Shen, Tjulandin, Hays, Starling, Xu, Sturtz, Fontaine, Oh, Brooks, Xu, Li, Li, Borodyansky, Van Cutsem (bb0095) 2022 Yu, Wang, Han, He (bb0115) 2012; 16 Smyth, Nilsson, Grabsch, van Grieken, Lordick (bb0020) 2020; 396 Joshi, Badgwell (bb0125) 2021; 71 Terashima, Kitada, Ochiai, Ichikawa, Kurahashi, Sakuramoto, Katai, Sano, Imamura, Sasako (bb0185) 2012; 18 Lo, Kolahi, Du, Chang, Krokhotin, Nair, Sobba, Karlsson, Jones, Longacre, Mah, Tercan, Sockell, Xu, Seoane, Chen, Shmulevich, Weissman, Curtis, Califano, Fu, Crabtree, Kuo (bb0150) 2021; 11 Seidlitz, Merker, Rothe, Zakrzewski, von Neubeck, Grutzmann, Sommer, Schweitzer, Scholch, Uhlemann, Gaebler, Werner, Krause, Baretton, Welsch, Koo, Aust, Klink, Weitz, Stange (bb0065) 2019; 68 Patel, Cecchini (bb0130) 2020; 21 Sung, Ferlay, Siegel, Laversanne, Soerjomataram, Jemal, Bray (bb0005) 2021; 71 Kretzschmar, Clevers (bb0040) 2016; 38 Sonbol, Ahn, Bekaii-Saab (bb0090) 2019; 7 Ychou, Boige, Pignon, Conroy, Bouche, Lebreton, Ducourtieux, Bedenne, Fabre, Saint-Aubert, Geneve, Lasser, Rougier (bb0135) 2011; 29 Chakrabarti, Koh, Steele, Hawkins, Ito, Merchant, Wang, Helmrath, Ahmad, So, Yong, Zavros (bb0160) 2021; 13 Kumar, Ramnarayanan, Sundar, Padmanabhan, Srivastava, Koiwa, Yasuda, Koh, Huang, Tay, Ho, Tan, Ishimoto, Kim, Shabbir, Chen, Zhang, Xu, Lam, Lum, Teh, Yong, So, Tan (bb0165) 2022; 12 N. Cancer Genome Atlas Research (bb0015) 2014; 513 Yoshida (bb0145) 2020; 13 Barra, Sarquis, Khayat, Khayat, Demachki, Anaissi, Ishak, Santos, Dos Santos, Burbano, Moreira, de Assumpcao (bb0175) 2021; 88 Wang, Yuen, Xu, Lee, Yan, Shi, Siu, Deng, Chu, Law, Chan, Chan, Tsui, Ho, Chan, Man, Foglizzo, Ng, Chan, Ching, Cheng, Xie, Fernandez, Li, Clevers, Rejto, Mao, Leung (bb0120) 2014; 46 Li, Zhang, Qiu, Wang, Mao, Hu, Chen, Du, Liu (bb0205) 2022; 2022 Aboulkheyr Es, Montazeri, Aref, Vosough, Baharvand (bb0060) 2018; 36 Kanehisa, Furumichi, Tanabe, Sato, Morishima (bb0110) 2017; 45 Lei, Teng, Tian, Chen, Xie, Wu, Zeng, Zeng, Pan, Chen, He (bb0190) 2022; 7 Hsieh, Kuo, Hsu, Tung, Li (bb0105) 2022; 15 Lazăr, Tăban, Cornianu, Faur, Goldiş (bb0195) 2016; 22 Cho (bb0050) 2020; 36 Sachs, Clevers (bb0035) 2014; 24 Nanki, Toshimitsu, Takano, Fujii, Shimokawa, Ohta, Matano, Seino, Nishikori, Ishikawa, Kawasaki, Togasaki, Takahashi, Sukawa, Ishida, Sugimoto, Kawakubo, Kim, Kitagawa, Sekine, Koo, Kanai, Sato (bb0080) 2018; 174 Li, Rogoff, Keates, Gao, Murikipudi, Mikule, Leggett, Li, Pardee, Li (bb0085) 2015; 112 Hunt, Camilleri, Crowe, El-Omar, Fox, Kuipers, Malfertheiner, McColl, Pritchard, Rugge, Sonnenberg, Sugano, Tack (bb0010) 2015; 64 Bleijs, van de Wetering, Clevers, Drost (bb0055) 2019; 38 Lei (10.1016/j.bbagen.2024.130566_bb0190) 2022; 7 Chakrabarti (10.1016/j.bbagen.2024.130566_bb0160) 2021; 13 Hunt (10.1016/j.bbagen.2024.130566_bb0010) 2015; 64 Lau (10.1016/j.bbagen.2024.130566_bb0045) 2020; 17 Zu (10.1016/j.bbagen.2024.130566_bb0170) 2023; 163 Aboulkheyr Es (10.1016/j.bbagen.2024.130566_bb0060) 2018; 36 Sachs (10.1016/j.bbagen.2024.130566_bb0035) 2014; 24 Li (10.1016/j.bbagen.2024.130566_bb0085) 2015; 112 Lindemann (10.1016/j.bbagen.2024.130566_bb0100) 2019; 25 Cho (10.1016/j.bbagen.2024.130566_bb0050) 2020; 36 Bang (10.1016/j.bbagen.2024.130566_bb0180) 2010; 376 Seidlitz (10.1016/j.bbagen.2024.130566_bb0065) 2019; 68 Patel (10.1016/j.bbagen.2024.130566_bb0130) 2020; 21 Lazăr (10.1016/j.bbagen.2024.130566_bb0195) 2016; 22 Sonbol (10.1016/j.bbagen.2024.130566_bb0090) 2019; 7 Kretzschmar (10.1016/j.bbagen.2024.130566_bb0040) 2016; 38 Sung (10.1016/j.bbagen.2024.130566_bb0005) 2021; 71 Ychou (10.1016/j.bbagen.2024.130566_bb0135) 2011; 29 Yin (10.1016/j.bbagen.2024.130566_bb0200) 2023; 10 Joshi (10.1016/j.bbagen.2024.130566_bb0125) 2021; 71 Greshock (10.1016/j.bbagen.2024.130566_bb0030) 2010; 70 Kanehisa (10.1016/j.bbagen.2024.130566_bb0110) 2017; 45 Chakrabarti (10.1016/j.bbagen.2024.130566_bb0155) 2021 Barra (10.1016/j.bbagen.2024.130566_bb0175) 2021; 88 Terashima (10.1016/j.bbagen.2024.130566_bb0185) 2012; 18 Li (10.1016/j.bbagen.2024.130566_bb0205) 2022; 2022 N. Cancer Genome Atlas Research (10.1016/j.bbagen.2024.130566_bb0015) 2014; 513 Bleijs (10.1016/j.bbagen.2024.130566_bb0055) 2019; 38 Wang (10.1016/j.bbagen.2024.130566_bb0120) 2014; 46 Smyth (10.1016/j.bbagen.2024.130566_bb0020) 2020; 396 Vlachogiannis (10.1016/j.bbagen.2024.130566_bb0070) 2018; 359 Yan (10.1016/j.bbagen.2024.130566_bb0075) 2018; 23 Shah (10.1016/j.bbagen.2024.130566_bb0095) 2022 Jeong (10.1016/j.bbagen.2024.130566_bb0025) 2023; 22 Nanki (10.1016/j.bbagen.2024.130566_bb0080) 2018; 174 Hsieh (10.1016/j.bbagen.2024.130566_bb0105) 2022; 15 van Hagen (10.1016/j.bbagen.2024.130566_bb0140) 2012; vol. 366 Kumar (10.1016/j.bbagen.2024.130566_bb0165) 2022; 12 Yoshida (10.1016/j.bbagen.2024.130566_bb0145) 2020; 13 Lo (10.1016/j.bbagen.2024.130566_bb0150) 2021; 11 Yu (10.1016/j.bbagen.2024.130566_bb0115) 2012; 16 |
| References_xml | – volume: 2022 start-page: 2353115 year: 2022 ident: bb0205 article-title: Energy-stress-mediated AMPK activation promotes GPX4-dependent Ferroptosis through the JAK2/STAT3/P53 Axis in renal Cancer publication-title: Oxidative Med. Cell. Longev. – volume: 36 start-page: 14 year: 2020 ident: bb0050 article-title: Patient-derived xenografts as compatible models for precision oncology publication-title: Lab. Anim. Res. – volume: 23 start-page: 882 year: 2018 end-page: 897 e811 ident: bb0075 article-title: A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening publication-title: Cell Stem Cell – volume: 38 year: 2019 ident: bb0055 article-title: Xenograft and organoid model systems in cancer research publication-title: EMBO J. – volume: 163 year: 2023 ident: bb0170 article-title: Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing publication-title: Biomed. Pharmacother. – volume: 10 year: 2023 ident: bb0200 article-title: PUM1 promotes tumor progression by activating DEPTOR-meditated glycolysis in gastric Cancer publication-title: Adv. Sci. (Weinh.) – volume: 71 start-page: 264 year: 2021 end-page: 279 ident: bb0125 article-title: Current treatment and recent progress in gastric cancer publication-title: CA Cancer J. Clin. – volume: 25 start-page: 5650 year: 2019 end-page: 5662 ident: bb0100 article-title: COTI-2, a novel Thiosemicarbazone derivative, exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms publication-title: Clin. Cancer Res. – volume: 7 start-page: 358 year: 2022 ident: bb0190 article-title: Signaling pathways and therapeutic interventions in gastric cancer publication-title: Sign. Transduct. Target. Ther. – volume: 15 year: 2022 ident: bb0105 article-title: -induced tumor mutation burden predicts poor survival of gastric cancer patients publication-title: Cancers (Basel) – volume: 70 start-page: 3677 year: 2010 end-page: 3686 ident: bb0030 article-title: Molecular target class is predictive of in vitro response profile publication-title: Cancer Res. – volume: 12 start-page: 670 year: 2022 end-page: 691 ident: bb0165 article-title: Single-cell atlas of lineage states, tumor microenvironment, and subtype-specific expression programs in gastric cancer publication-title: Cancer Discov. – volume: 68 start-page: 207 year: 2019 end-page: 217 ident: bb0065 article-title: Human gastric cancer modelling using organoids publication-title: Gut – volume: 396 start-page: 635 year: 2020 end-page: 648 ident: bb0020 article-title: Gastric cancer publication-title: Lancet – year: 2021 ident: bb0155 article-title: A preclinical human-derived autologous gastric cancer organoid/immune cell co-culture model to predict the efficacy of targeted therapies publication-title: J. Vis. Exp. – volume: 13 year: 2021 ident: bb0160 article-title: Disruption of Her2-induced PD-L1 inhibits tumor cell immune evasion in patient-derived gastric cancer organoids publication-title: Cancers (Basel) – volume: 376 start-page: 687 year: 2010 end-page: 697 ident: bb0180 article-title: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial publication-title: Lancet – volume: 45 start-page: D353 year: 2017 end-page: D361 ident: bb0110 article-title: KEGG: new perspectives on genomes, pathways, diseases and drugs publication-title: Nucleic Acids Res. – volume: 21 start-page: 70 year: 2020 ident: bb0130 article-title: Targeted therapies in advanced gastric Cancer publication-title: Curr. Treat. Options in Oncol. – volume: 359 start-page: 920 year: 2018 end-page: 926 ident: bb0070 article-title: Patient-derived organoids model treatment response of metastatic gastrointestinal cancers publication-title: Science – volume: 17 start-page: 203 year: 2020 end-page: 222 ident: bb0045 article-title: Organoid models of gastrointestinal cancers in basic and translational research publication-title: Nat. Rev. Gastroenterol. Hepatol. – volume: 22 start-page: 6776 year: 2016 end-page: 6799 ident: bb0195 article-title: New advances in targeted gastric cancer treatment publication-title: World J. Gastroenterol. – volume: 38 start-page: 590 year: 2016 end-page: 600 ident: bb0040 article-title: Organoids: modeling development and the stem cell niche in a dish publication-title: Dev. Cell – volume: 112 start-page: 1839 year: 2015 end-page: 1844 ident: bb0085 article-title: Suppression of cancer relapse and metastasis by inhibiting cancer stemness publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 7 year: 2019 ident: bb0090 article-title: Therapeutic targeting strategies of cancer stem cells in gastrointestinal malignancies publication-title: Biomedicines – volume: 13 start-page: 4 year: 2020 ident: bb0145 article-title: Applications of patient-derived tumor xenograft models and tumor organoids publication-title: J. Hematol. Oncol. – volume: 18 start-page: 5992 year: 2012 end-page: 6000 ident: bb0185 article-title: Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer publication-title: Clin. Cancer Res. – volume: 36 start-page: 358 year: 2018 end-page: 371 ident: bb0060 article-title: Personalized Cancer medicine: an organoid approach publication-title: Trends Biotechnol. – start-page: OF1 year: 2022 end-page: OF9 ident: bb0095 article-title: Randomized, double-blind, placebo-controlled Phase III Study of Paclitaxel +/− Napabucasin in pretreated advanced gastric or gastroesophageal junction Adenocarcinoma publication-title: Clin. Cancer Res. – volume: 22 start-page: 147 year: 2023 ident: bb0025 article-title: Clinically conserved genomic subtypes of gastric adenocarcinoma publication-title: Mol. Cancer – volume: 16 start-page: 284 year: 2012 end-page: 287 ident: bb0115 article-title: clusterProfiler: an R package for comparing biological themes among gene clusters publication-title: OMICS – volume: 513 start-page: 202 year: 2014 end-page: 209 ident: bb0015 article-title: Comprehensive molecular characterization of gastric adenocarcinoma publication-title: Nature – volume: 71 start-page: 209 year: 2021 end-page: 249 ident: bb0005 article-title: Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA Cancer J. Clin. – volume: 29 start-page: 1715 year: 2011 end-page: 1721 ident: bb0135 article-title: Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial publication-title: J. Clin. Oncol. – volume: 88 start-page: 156 year: 2021 end-page: 169 ident: bb0175 article-title: Gastric cancer microbiome publication-title: Pathobiology – volume: 24 start-page: 68 year: 2014 end-page: 73 ident: bb0035 article-title: Organoid cultures for the analysis of cancer phenotypes publication-title: Curr. Opin. Genet. Dev. – volume: 174 start-page: 856 year: 2018 end-page: 869 e817 ident: bb0080 article-title: Divergent routes toward Wnt and R-spondin niche independency during human gastric carcinogenesis publication-title: Cell – volume: vol. 366 start-page: 2074 year: 2012 end-page: 2084 ident: bb0140 article-title: Preoperative chemoradiotherapy for esophageal or junctional cancer publication-title: N. Engl. J. Med. – volume: 11 start-page: 1562 year: 2021 end-page: 1581 ident: bb0150 article-title: A CRISPR/Cas9-engineered ARID1A-deficient human gastric Cancer organoid model reveals essential and nonessential modes of oncogenic transformation publication-title: Cancer Discov. – volume: 64 start-page: 1650 year: 2015 end-page: 1668 ident: bb0010 article-title: The stomach in health and disease publication-title: Gut – volume: 46 start-page: 573 year: 2014 end-page: 582 ident: bb0120 article-title: Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer publication-title: Nat. Genet. – volume: 38 year: 2019 ident: 10.1016/j.bbagen.2024.130566_bb0055 article-title: Xenograft and organoid model systems in cancer research publication-title: EMBO J. doi: 10.15252/embj.2019101654 – volume: 13 start-page: 4 year: 2020 ident: 10.1016/j.bbagen.2024.130566_bb0145 article-title: Applications of patient-derived tumor xenograft models and tumor organoids publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-019-0829-z – volume: 174 start-page: 856 year: 2018 ident: 10.1016/j.bbagen.2024.130566_bb0080 article-title: Divergent routes toward Wnt and R-spondin niche independency during human gastric carcinogenesis publication-title: Cell doi: 10.1016/j.cell.2018.07.027 – volume: 71 start-page: 209 year: 2021 ident: 10.1016/j.bbagen.2024.130566_bb0005 article-title: Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21660 – volume: 376 start-page: 687 year: 2010 ident: 10.1016/j.bbagen.2024.130566_bb0180 article-title: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(10)61121-X – volume: 88 start-page: 156 year: 2021 ident: 10.1016/j.bbagen.2024.130566_bb0175 article-title: Gastric cancer microbiome publication-title: Pathobiology doi: 10.1159/000512833 – volume: 163 year: 2023 ident: 10.1016/j.bbagen.2024.130566_bb0170 article-title: Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2023.114751 – volume: 25 start-page: 5650 year: 2019 ident: 10.1016/j.bbagen.2024.130566_bb0100 article-title: COTI-2, a novel Thiosemicarbazone derivative, exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-19-0096 – start-page: OF1 year: 2022 ident: 10.1016/j.bbagen.2024.130566_bb0095 article-title: Randomized, double-blind, placebo-controlled Phase III Study of Paclitaxel +/− Napabucasin in pretreated advanced gastric or gastroesophageal junction Adenocarcinoma publication-title: Clin. Cancer Res. – year: 2021 ident: 10.1016/j.bbagen.2024.130566_bb0155 article-title: A preclinical human-derived autologous gastric cancer organoid/immune cell co-culture model to predict the efficacy of targeted therapies publication-title: J. Vis. Exp. doi: 10.3791/61443 – volume: 64 start-page: 1650 year: 2015 ident: 10.1016/j.bbagen.2024.130566_bb0010 article-title: The stomach in health and disease publication-title: Gut doi: 10.1136/gutjnl-2014-307595 – volume: 36 start-page: 358 year: 2018 ident: 10.1016/j.bbagen.2024.130566_bb0060 article-title: Personalized Cancer medicine: an organoid approach publication-title: Trends Biotechnol. doi: 10.1016/j.tibtech.2017.12.005 – volume: 7 year: 2019 ident: 10.1016/j.bbagen.2024.130566_bb0090 article-title: Therapeutic targeting strategies of cancer stem cells in gastrointestinal malignancies publication-title: Biomedicines doi: 10.3390/biomedicines7010017 – volume: 10 year: 2023 ident: 10.1016/j.bbagen.2024.130566_bb0200 article-title: PUM1 promotes tumor progression by activating DEPTOR-meditated glycolysis in gastric Cancer publication-title: Adv. Sci. (Weinh.) – volume: 68 start-page: 207 year: 2019 ident: 10.1016/j.bbagen.2024.130566_bb0065 article-title: Human gastric cancer modelling using organoids publication-title: Gut doi: 10.1136/gutjnl-2017-314549 – volume: 29 start-page: 1715 year: 2011 ident: 10.1016/j.bbagen.2024.130566_bb0135 article-title: Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2010.33.0597 – volume: 23 start-page: 882 year: 2018 ident: 10.1016/j.bbagen.2024.130566_bb0075 article-title: A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening publication-title: Cell Stem Cell doi: 10.1016/j.stem.2018.09.016 – volume: 70 start-page: 3677 year: 2010 ident: 10.1016/j.bbagen.2024.130566_bb0030 article-title: Molecular target class is predictive of in vitro response profile publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-09-3788 – volume: 12 start-page: 670 year: 2022 ident: 10.1016/j.bbagen.2024.130566_bb0165 article-title: Single-cell atlas of lineage states, tumor microenvironment, and subtype-specific expression programs in gastric cancer publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-21-0683 – volume: 21 start-page: 70 year: 2020 ident: 10.1016/j.bbagen.2024.130566_bb0130 article-title: Targeted therapies in advanced gastric Cancer publication-title: Curr. Treat. Options in Oncol. doi: 10.1007/s11864-020-00774-4 – volume: 38 start-page: 590 year: 2016 ident: 10.1016/j.bbagen.2024.130566_bb0040 article-title: Organoids: modeling development and the stem cell niche in a dish publication-title: Dev. Cell doi: 10.1016/j.devcel.2016.08.014 – volume: 359 start-page: 920 year: 2018 ident: 10.1016/j.bbagen.2024.130566_bb0070 article-title: Patient-derived organoids model treatment response of metastatic gastrointestinal cancers publication-title: Science doi: 10.1126/science.aao2774 – volume: 13 year: 2021 ident: 10.1016/j.bbagen.2024.130566_bb0160 article-title: Disruption of Her2-induced PD-L1 inhibits tumor cell immune evasion in patient-derived gastric cancer organoids publication-title: Cancers (Basel) doi: 10.3390/cancers13246158 – volume: 46 start-page: 573 year: 2014 ident: 10.1016/j.bbagen.2024.130566_bb0120 article-title: Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer publication-title: Nat. Genet. doi: 10.1038/ng.2983 – volume: 16 start-page: 284 year: 2012 ident: 10.1016/j.bbagen.2024.130566_bb0115 article-title: clusterProfiler: an R package for comparing biological themes among gene clusters publication-title: OMICS doi: 10.1089/omi.2011.0118 – volume: vol. 366 start-page: 2074 year: 2012 ident: 10.1016/j.bbagen.2024.130566_bb0140 article-title: Preoperative chemoradiotherapy for esophageal or junctional cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1112088 – volume: 15 year: 2022 ident: 10.1016/j.bbagen.2024.130566_bb0105 article-title: Fusobacterium Nucleatum-induced tumor mutation burden predicts poor survival of gastric cancer patients publication-title: Cancers (Basel) doi: 10.3390/cancers15010269 – volume: 7 start-page: 358 year: 2022 ident: 10.1016/j.bbagen.2024.130566_bb0190 article-title: Signaling pathways and therapeutic interventions in gastric cancer publication-title: Sign. Transduct. Target. Ther. doi: 10.1038/s41392-022-01190-w – volume: 2022 start-page: 2353115 year: 2022 ident: 10.1016/j.bbagen.2024.130566_bb0205 article-title: Energy-stress-mediated AMPK activation promotes GPX4-dependent Ferroptosis through the JAK2/STAT3/P53 Axis in renal Cancer publication-title: Oxidative Med. Cell. Longev. doi: 10.1155/2022/2353115 – volume: 36 start-page: 14 year: 2020 ident: 10.1016/j.bbagen.2024.130566_bb0050 article-title: Patient-derived xenografts as compatible models for precision oncology publication-title: Lab. Anim. Res. doi: 10.1186/s42826-020-00045-1 – volume: 71 start-page: 264 year: 2021 ident: 10.1016/j.bbagen.2024.130566_bb0125 article-title: Current treatment and recent progress in gastric cancer publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21657 – volume: 22 start-page: 147 year: 2023 ident: 10.1016/j.bbagen.2024.130566_bb0025 article-title: Clinically conserved genomic subtypes of gastric adenocarcinoma publication-title: Mol. Cancer doi: 10.1186/s12943-023-01796-w – volume: 112 start-page: 1839 year: 2015 ident: 10.1016/j.bbagen.2024.130566_bb0085 article-title: Suppression of cancer relapse and metastasis by inhibiting cancer stemness publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.1424171112 – volume: 24 start-page: 68 year: 2014 ident: 10.1016/j.bbagen.2024.130566_bb0035 article-title: Organoid cultures for the analysis of cancer phenotypes publication-title: Curr. Opin. Genet. Dev. doi: 10.1016/j.gde.2013.11.012 – volume: 11 start-page: 1562 year: 2021 ident: 10.1016/j.bbagen.2024.130566_bb0150 article-title: A CRISPR/Cas9-engineered ARID1A-deficient human gastric Cancer organoid model reveals essential and nonessential modes of oncogenic transformation publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-20-1109 – volume: 22 start-page: 6776 year: 2016 ident: 10.1016/j.bbagen.2024.130566_bb0195 article-title: New advances in targeted gastric cancer treatment publication-title: World J. Gastroenterol. doi: 10.3748/wjg.v22.i30.6776 – volume: 17 start-page: 203 year: 2020 ident: 10.1016/j.bbagen.2024.130566_bb0045 article-title: Organoid models of gastrointestinal cancers in basic and translational research publication-title: Nat. Rev. Gastroenterol. Hepatol. doi: 10.1038/s41575-019-0255-2 – volume: 45 start-page: D353 year: 2017 ident: 10.1016/j.bbagen.2024.130566_bb0110 article-title: KEGG: new perspectives on genomes, pathways, diseases and drugs publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkw1092 – volume: 18 start-page: 5992 year: 2012 ident: 10.1016/j.bbagen.2024.130566_bb0185 article-title: Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-12-1318 – volume: 396 start-page: 635 year: 2020 ident: 10.1016/j.bbagen.2024.130566_bb0020 article-title: Gastric cancer publication-title: Lancet doi: 10.1016/S0140-6736(20)31288-5 – volume: 513 start-page: 202 year: 2014 ident: 10.1016/j.bbagen.2024.130566_bb0015 article-title: Comprehensive molecular characterization of gastric adenocarcinoma publication-title: Nature doi: 10.1038/nature13480 |
| SSID | ssj0000595 |
| Score | 2.4392378 |
| Snippet | Gastric cancer (GC) is a highly heterogeneous disease featuring many various histological and molecular subtypes. Therefore, it is imperative to have... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 130566 |
| SubjectTerms | Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use COTI-2 Drug Evaluation, Preclinical Early Detection of Cancer Gastric cancer Humans Napabucasin Organoids Organoids biobank Personalized medicine Stomach Neoplasms - drug therapy Stomach Neoplasms - pathology |
| Title | Gastric cancer patient-derived organoids model for the therapeutic drug screening |
| URI | https://dx.doi.org/10.1016/j.bbagen.2024.130566 https://www.ncbi.nlm.nih.gov/pubmed/38244703 https://www.proquest.com/docview/2918511090 |
| Volume | 1868 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3daxQxEB9KRfRFtH5drSWCr_E2m2w2-1gO66lYEC30LeRTrshdud4Jvvi3d2azWysoBR93SdgwM5n5ZTMzP4DXIaqIUbfjWoXMVZaKG-EE10aHoGPduUT_Oz6d6Pmp-nDWnO3AbKyFobTKwfcXn9576-HNdJDm9GKxmH6hSz2EEw1lQRISpwp21ZKVv_n1O80D4UNTbhIUp9Fj-Vyf4-U9blrqglorokVu-l6Jfw1P_4KffRg6fggPBvzIjsoSH8FOWu7B3cIo-XMP7s1GArfH8PmdI1KOwAJpds2GFqo8otH9SJH1hE6rRbxkPR0OQ_jKEA6yGyVZLK633xh6FjztYox7AqfHb7_O5nxgUOABA9OGpxq3V3S5DVJIFRFL5U6ZWAkTfQ4-6thEV2vjY2u0k7l2le9CFWsVhEltkk9hd7lapufAchWcSLnqMh6wmpx8likZqUyuvRDaTUCOgrNhaC9OLBff7ZhHdm6LuC2J2xZxT4Bfz7oo7TVuGd-OOrF_mInFCHDLzFejCi3qga5F3DKttpe27gTBzqqrJvCs6PZ6LdIg_EGnuP_f330B9-mpJPscwO5mvU0vEcds_GFvqIdw5-j9x_nJFS-f8cE |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3daxQxEB_qFakvUqvW06oRfA232WRz2cdyWK-2PRBb6FvIp5yUu3K9K_S_d2Y_qoJS8HU3w4aZycwvm8n8AD6GqCJm3ZprFTJXWSpuhBNcGx2CjmXtEv3vOJvp6YX6clldbsGkvwtDZZVd7G9jehOtuyejTpuj6_l89I0O9RBOVFQFSUj8EWxTd6pqANuHxyfT2a-AXDXkKzSek0B_g64p8_Ie1y01Qi0VMSNXTbvEv2aofyHQJhMd7cLTDkKyw3aWz2ArLfbgcUsqebcHO5Oew-05fP3siJcjsEDGXbGuiyqP6He3KbKG02k5jzesYcRhiGAZIkL2260sFleb7wyDC254Mc29gIujT-eTKe9IFHjA3LTmqcQVFl0eBymkigincq1MLISJPgcfdayiK7XxcWy0k7l0ha9DEUsVhEnjJF_CYLFcpFfAchGcSLmoM-6xqpx8likZqUwuvRDaDUH2irOh6zBORBdXti8l-2FbdVtSt23VPQR-L3Xddth4YPy4t4n9w1MsJoEHJD_0JrRoBzoZcYu03NzYshaEPIu6GMJ-a9v7uUiDCAjj4uv__u572Jmen53a0-PZyRt4Qm_a2p8DGKxXm_QWYc3av-vc9id66vRy |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Gastric+cancer+patient-derived+organoids+model+for+the+therapeutic+drug+screening&rft.jtitle=Biochimica+et+biophysica+acta.+General+subjects&rft.au=Xu%2C+Jiao&rft.au=Gong%2C+Jin&rft.au=Li%2C+Mengyang&rft.au=Kang%2C+Ye&rft.date=2024-04-01&rft.pub=Elsevier+B.V&rft.issn=0304-4165&rft.eissn=1872-8006&rft.volume=1868&rft.issue=4&rft_id=info:doi/10.1016%2Fj.bbagen.2024.130566&rft.externalDocID=S0304416524000096 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0304-4165&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0304-4165&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0304-4165&client=summon |